Recommended

FDA tightens COVID vaccine use
Decentralised manufacturing consortium launched
Trial boost for myasthenia gravis drug
FDA starts publishing daily AE data
WEBINAR | The Future of Sterility Testing: One-Day Results with Advanced RT-rt PCR Technology | 5 NOV
WEBINAR | Mastering Impurity Profiling: USP’s Evolving Standards and Strategies | 15 OCT
news

FDA expands emergency use authorisation for remdesivir to treat all COVID-19 patients

12
SHARES

The FDA has expanded the Emergency Use Authorisation for Veklury (remdesivir) to treat all hospitalised patients with COVID-19.

Gilead Sciences has announced that the US Food and Drug Administration (FDA) has expanded the emergency use authorisation (EUA) that enables the use of the investigational antiviral Veklury (remdesivir) to treat all hospitalised patients with COVID-19. The update is in addition to the previous authorisation for patients hospitalised with severe COVID-19.

 

ACCESS your FREE COPY

 


This report addresses the key factors shaping pharmaceutical formulation, including regulation, QC and analysis.

Access the full report now to discover the techniques, tools and innovations that are transforming pharmaceutical formulation, and learn how to position your organisation for long-term success.

What you’ll discover:

  • Key trends shaping the pharmaceutical formulation sector
  • Innovations leading progress in pharmaceutical formulation and how senior professionals can harness their benefits
  • Considerations and best practices when utilising QbD during formulation of oral solid dosage forms
  • And more!

Don’t miss your chance to access this exclusive report ! Access now – it’s free

The expanded EUA is based on results from a Phase III trial evaluating Veklury in hospitalised patients with moderate COVID-19 pneumonia, as well as results from a US National Institute of Allergy and Infectious Diseases (NIAID) trial in hospitalised patients with a range of disease severity.

The drug is an investigational nucleotide analogue with broad-spectrum antiviral activity both in vitro and in vivo in animal models against multiple emerging viral pathogens. 

Gilead conducted two randomised, open-label, multi-centre international Phase III clinical trials for the investigational drug in countries with a high prevalence of COVID-19 infections. The data published demonstrated that Veklury was generally well-tolerated in both five-day and 10-day treatment groups. 

“With the growing understanding of the utility of Veklury to help improve outcomes for a range of patients with COVID-19, we welcome the FDA’s decision to expand emergency use authorisation,” said Dr Merdad Parsey, Chief Medical Officer at Gilead Sciences. “As we learn more about COVID-19 and we further establish the efficacy and safety profile of Veklury, we see benefit to making the drug available to patients at earlier stages of the disease. Today’s action by the FDA enables physicians to consider a broader range of eligible patients to potentially receive Veklury.”

“As our understanding of the spectrum of SARS-CoV-2 infection and the presentations and severity of COVID-19 continues to evolve, these results and the expanded EUA represent a new, important step that streamlines bedside prescribing of remdesivir without having to wait for patients to worsen clinically,” said Dr Francisco Marty, an infectious diseases physician at Brigham and Women’s Hospital and associate professor of medicine at Harvard Medical School. 

Share via
Share via